Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04530747 · ClinicalTrials.gov registry record · Phase 1
Metabolic Effects of Metformin Therapy in Obstructive Sleep Apnea
A Phase 1 study, sponsored by Pennington Biomedical Research Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT04530747 is a Phase 1 study that was terminated before completion, run by Pennington Biomedical Research Center. The registered enrollment target is 16 participants.
The verdict
NCT04530747, a Phase 1 study, was terminated before completion, sponsored by Pennington Biomedical Research Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of the study is to see if metformin improves metabolism in patients with obstructive sleep apnea (OSA) using positive airway pressure (PAP) therapy. Metformin is approved by the Food and Drug Administration (FDA) for the treatment and prevention of diabetes. It is not approved for use in patients with OSA.
Interventions
- DRUG Metformin + PAP
- DRUG Placebo oral capsule + PAP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2021-01-28 |
| Est. Completion | 2021-11-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04530747
The ClinicalTrials.gov registry entry for NCT04530747 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pennington Biomedical Research Center, which has 258 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Metformin + PAP is the first listed.
NCT04530747 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04530747 about?
NCT04530747 is a clinical study titled "Metabolic Effects of Metformin Therapy in Obstructive Sleep Apnea". The purpose of the study is to see if metformin improves metabolism in patients with obstructive sleep apnea (OSA) using positive airway pressure (PAP) therapy. Metformin is approved by the Food and Drug Administration (FDA) for the treatment and prevention of diabetes. It is not approved for use in...
What is the current status of trial NCT04530747?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2021-01-28. Estimated completion is 2021-11-30.
What interventions are being tested in trial NCT04530747?
The interventions under investigation include: Metformin + PAP (DRUG), Placebo oral capsule + PAP (DRUG).
Who is sponsoring clinical trial NCT04530747?
This trial is sponsored by Pennington Biomedical Research Center, which has 258 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.